Compare CASH & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CASH | VOR |
|---|---|---|
| Founded | 1954 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 1996 | 2021 |
| Metric | CASH | VOR |
|---|---|---|
| Price | $78.48 | $22.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $107.50 | $45.33 |
| AVG Volume (30 Days) | 181.5K | ★ 697.7K |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.23% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 6.29 | N/A |
| Revenue | ★ $839,894,000.00 | N/A |
| Revenue This Year | $7.56 | N/A |
| Revenue Next Year | $6.02 | N/A |
| P/E Ratio | $12.58 | ★ N/A |
| Revenue Growth | ★ 11.29 | N/A |
| 52 Week Low | $65.93 | $6.50 |
| 52 Week High | $101.26 | $49.95 |
| Indicator | CASH | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 32.06 | 47.59 |
| Support Level | $76.80 | $21.90 |
| Resistance Level | $85.41 | $24.44 |
| Average True Range (ATR) | 1.55 | 1.13 |
| MACD | -0.23 | -0.19 |
| Stochastic Oscillator | 8.10 | 12.44 |
Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.